XML 50 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Deferred revenue, net of current ($9,381 and $4,636 to a related party) $ 152,865 $ 138,474
Deferred Revenue 5,256 2,147
Net unbilled co-development revenue 0 0
AstraZeneca Agreements [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Deferred Revenue 149,759 $ 137,338
Net unbilled co-development revenue 5,300  
AstraZeneca Agreements [Member] | U.S./RoW [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Deferred revenue, net of current ($9,381 and $4,636 to a related party) 146,800  
Deferred Revenue 152,100  
Net unbilled co-development revenue $ 5,300